1-3 of 3
Steven Gore
Close
Sort by
Journal Articles

Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure

Brian Ball, MD, Rami S. Komrokji, MD, Lionel Ades, MD PhD, Mikkael A. Sekeres, MD MS, Amy E. DeZern, MD MHS, Lisa Pleyer, MD DI, Norbert Vey, MD PhD, Antonio Almeida, MD PhD, Ulrich Germing, Thomas Cluzeau, Uwe Platzbecker, MD, Steven Gore, Pierre Fenaux, MD PhD, Thomas Prebet, MD PhD
Journal: Blood
Blood (2016) 128 (22): 348.
https://doi.org/10.1182/blood.V128.22.348.348
Published: 2016
Journal Articles

Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study

Amer M. Zeidan, MBBS, MHS, Xin Hu, Jessica B. Long, PhD, Rong Wang, PhD, Scott F Huntington, MDMPH, Nikolai A Podoltsev, MD PhD, Steven Gore, Xiaomei Ma, PhD, Amy J. Davidoff, PhD
Journal: Blood
Blood (2016) 128 (22): 394.
https://doi.org/10.1182/blood.V128.22.394.394
Published: 2016
Journal Articles

Report of an international working group to standardize response criteria for myelodysplastic syndromes

Clinical Trials & Observations
Bruce D. Cheson, John M. Bennett, Hagop Kantarjian, Antonio Pinto, Charles A. Schiffer, Stephen D. Nimer, Bob Löwenberg, Miroslav Beran, Theo M. de Witte, Richard M. Stone, Moshe Mittelman, Guillermo F. Sanz, Pierre W. Wijermans, Steven Gore, Peter L. Greenberg
Journal: Blood
Blood (2000) 96 (12): 3671–3674.
https://doi.org/10.1182/blood.V96.12.3671
Published: 2000